International Medical Journal, Vol. 23., Iss. 2, 2017, P. 78−85.
IMPROVEMENT OF QUALITY OF LIFE IN PATIENTS WITH PAIN SYNDROMES AND DYSPHAGIA OF VARIOUS ETIOLOGY
Kharkiv National Medical University, Ukraine
This work assessed quality of life in the dynamics of the traditional therapy with addition of Movixicam OTD (Switzerland) on the example of groups of patients with pain and dysphagia against a background of various neurological disorders as well as battle combined brain and maxillofacial injury. In addition to clinical and neurological examination, international questionnaires, visual analogue scale of pain (VAS) and a questionnaire MOS SF−36, allowing objective estimation of the state of the patients were used. Comparison of the results before and after the treatment allowed estimating the dynamics of the patient's perception of their pain and quality of life. The study showed high efficacy of the drug Movixicam OTD in treatment of patients with pain syndrome of various etiologies against a background of dysphagia. Therapeutic effect of different degree was observed in 98 % of patients. The therapy resulted in a significant regression of the pain intensity, and therefore the degree of restriction of motor function. The indices of the quality of life in all cases had a positive trend, which undoubtedly influenced both the physical and psychological adaptation of patients. Ease of application of oral dispenser forms of meloxicam in the form Moviksikam ODT expands its range of application even in patients with impaired swallowing function. A very important advantage is that the drug does not increase the risk of myocardial infarction, heart failure, edema and hypertension, which makes possible its use in patients with acute and chronic circulatory disorders amid rheumatic diseases and associated cranial and maxillofacial injuries.
Key words: pain syndrome, dysphagia, therapy, moviksikam ODT.